1月3日,国家食品药品监督管理总局、国家卫生计生委联合通报乙肝疫苗问题调查进展:未发现深圳康泰公司生产的疫苗存在质量问题。目前累计报告的17例疑似因接种致死病例中,9例已明确诊断与接种疫苗无关,其他8例初步诊断也与接种疫苗无关。1例已康复出院的重症病例,不排除接种康泰产乙肝疫苗引起的异常反应(过敏性休克)。 January 3, the State Food and Drug Administration, the National Health and Family Planning Commission jointly informed Hepatitis B vaccine investigation progress: no found in Shenzhen Kangtai vaccine production quality problems. The current cumulative reported 17 cases of suspected deaths due to vaccination, 9 cases have been diagnosed with vaccination has nothing to do, and the other 8 cases of initial diagnosis has nothing to do with vaccination. One patient had recovered from severe cases and did not rule out the abnormal reaction (anaphylactic shock) caused by inoculating Kangtai-produced hepatitis B vaccine.